Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;29(4):1227-1231.
doi: 10.1111/ene.15221. Epub 2021 Dec 29.

Factors associated with augmentation in patients with restless legs syndrome

Beatrice Heim  1 , Philipp Ellmerer  1 , Ambra Stefani  1 , Melanie Bergmann  1 , Elisabeth Brandauer  1 , Klaus Seppi  1 , Birgit Högl  1 , Atbin Djamshidian  1
Affiliations

Factors associated with augmentation in patients with restless legs syndrome

Beatrice Heim et al. Eur J Neurol. 2022 Apr.

Abstract

Background and purpose: Augmentation is a paradoxical reaction mainly to dopaminergic medication in patients with restless legs syndrome (RLS), but the exact pathomechanism remains unclear. The aim of this study was to identify factors associated with augmentation in RLS patients.

Methods: RLS patients with and without current or previous augmentation were recruited. Demographic characteristics, history of smoking, questionnaires for depression, alexithymia, and impulsivity, and RLS severity were obtained.

Results: We included 122 patients, of whom half had a history of augmentation. Patients with augmentation had a longer disease duration (p = 0.001), had higher RLS severity scores (p = 0.013), had higher levodopa equivalent doses (p < 0.001), had higher scores for alexithymia (p = 0.028), had higher prevalence of impulse control disorders (p < 0.001), more often had a history of smoking (p = 0.039), were more often currently smoking (p = 0.015), and had more average pack-years (p = 0.016).

Conclusions: Here, we describe several factors commonly associated with augmentation in RLS. These may help clinicians to screen and treat patients carefully to avoid the challenging side effect of augmentation.

Keywords: RLS; augmentation; impulsivity; neurobehavioral changes.

PubMed Disclaimer

Conflict of interest statement

None.

References

    1. Allen RP, Ondo WG, Ball E, et al. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med. 2011;12(5):431‐439. - PubMed
    1. Garcia‐Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first‐line treatment of restless legs syndrome/Willis–Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS‐foundation. Sleep Med. 2016;21:1‐11. - PubMed
    1. Earley CJ, Uhl GR, Clemens S, Ferré S. Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation. Sleep Med. 2017;31:71‐77. - PMC - PubMed
    1. Heim B, Djamshidian A, Heidbreder A, et al. Augmentation and impulsive behaviors in restless legs syndrome: coexistence or association? Neurology. 2016;87(1):36‐40. - PubMed
    1. Mitterling T, Frauscher B, Falkenstetter T, et al. Is there a polysomnographic signature of augmentation in restless legs syndrome? Sleep Med. 2014;15(10):1231‐1240. - PubMed

MeSH terms